Radius Health Inc. buy tamam
Start price
30.01.18
/
50%
€35.46
Target price
04.11.21
€21.41
Performance (%)
-47.87%
End price
05.11.21
€18.49
Summary
This prediction ended on 05.11.21 with a price of €18.49. Massive losses of -47.87% were the result for the BUY prediction by tamam. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Radius Health Inc. | - | - | - | - |
| iShares Core DAX® | 1,43 % | 2,63 % | 12,46 % | 60,35 % |
| iShares Nasdaq 100 | 1,89 % | -0,46 % | 1,25 % | 85,81 % |
| iShares Nikkei 225® | -1,62 % | 11,10 % | 27,38 % | 64,40 % |
| iShares S&P 500 | 1,92 % | 1,16 % | 1,63 % | 59,42 % |
Comments by tamam for this prediction
In the thread Radius Health Inc. diskutieren
Radius Health could Advance 50% With Osteoporosis Treatment
Morgan Stanley analyst initiated coverage of the company with an Overweight rating and a $57 price target.
Radius is set to launch Tymlos, a bone builder for women with osteoporosis, but despite Eli Lilly's presence in the market with Forteo, which fetched the company $1 billion in sales and is exposed to generic competition in 2019, the analyst said Tymlos' pricing is 40 percent lower than Forteo's — and
convenience could help it grab share.
Radius Health is a Conviction Buy!
Kursziel geändert auf 41,414
Kursziel geändert auf 21,414
In the thread Trading Radius Health Inc.
Die von tamam gewählte maximale Laufzeit wurde überschritten